Inhibikase Therapeutics (IKT) Metrics: History & Chart

Inhibikase Therapeutics, Inc.(IKT)

Biotechnology · Wilmington, DE

$1.98-0.02 (-1.00%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.

Wilmington, DE

35 employees

www.inhibikase.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Mark T. Iwicki

View full financials

Third-Party DCF Estimate (FMP)	$1.41
Price Gap vs Third-Party Estimate	-29.73%

7D Total Return	-2.44%
30D Total Return	-20.00%
YTD Total Return	-2.44%
1Y Total Return	+20.48%
3Y Total Return	+122.24%
5Y Total Return	-82.08%
10Y Total Return	N/A
15Y Total Return	N/A
20Y Total Return	N/A

2026	-2.44%
2025	-36.92%
2024	+155.91%
2023	-57.67%
2022	-65.99%
2021	-78.70%
2020

CAGR TTM	+20.37%
CAGR 3Y	+30.49%
CAGR 5Y	-29.10%
CAGR 10Y	N/A
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	N/A
PE Ratio Avg TTM	N/A
PE Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

All Metrics

IKT Valuation Metrics

IKT Stock Price Metrics

IKT Dividend Metrics

IKT Growth Rate Metrics

IKT Discounted Cash Flow Metrics

IKT Returns By Period

IKT Yearly Returns

IKT Average Annual Returns By Period (CAGR)

IKT Revenue Metrics

IKT PE Ratio Metrics

IKT PS Ratio Metrics

IKT PB Ratio Metrics

IKT Price to Free Cash Flow Ratio Metrics

IKT Debt to Equity Ratio Metrics

IKT PEG Ratio Metrics

IKT FCF Yield

IKT Earnings Yield

IKT EBITDA Yield

IKT OCF Yield

IKT EV/EBIT Ratio Metrics

IKT EV/EBITDA Ratio Metrics

IKT EV/Assets Ratio Metrics

IKT EV/Sales Ratio Metrics

IKT Current Ratio Metrics

IKT Quick Ratio Metrics

IKT ROIC Metrics

IKT Return on Assets Metrics

IKT Return on Equity Metrics

IKT Net Profit Margin Metrics

IKT Gross Profit Margin Metrics

IKT Tax Rate Metrics

PS Ratio	21051690.90
PS Ratio Avg TTM	8336935.98
PS Ratio Avg 3Y	98.58
Current VS TTM Avg	+152.51%
Current VS 3Y Avg	+21355801.51%
Current VS 5Y Avg	+28915884.50%

PB Ratio	2.28
PB Ratio Avg TTM	1.99
PB Ratio Avg 3Y	1.54
Current VS TTM Avg	+14.50%
Current VS 3Y Avg	+48.43%
Current VS 5Y Avg	+96.83%

PFCF Ratio	N/A
PFCF Ratio Avg TTM	N/A
PFCF Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Debt/Equity Ratio	0.00
Debt/Equity Ratio Avg TTM	0.00
Debt/Equity Ratio Avg 3Y	0.00
Current VS TTM Avg	-100.00%
Current VS 3Y Avg	-100.00%
Current VS 5Y Avg	-100.00%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	N/A
FCF Yield Avg TTM	N/A
FCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Earnings Yield	N/A
Earnings Yield Avg TTM	N/A
Earnings Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	N/A
Ev/Ebit Ratio Avg TTM	N/A
Ev/Ebit Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebitda Ratio	N/A
Ev/Ebitda Ratio Avg TTM	N/A
Ev/Ebitda Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Assets Ratio	1.94
Ev/Assets Ratio Avg TTM	1.44
Ev/Assets Ratio Avg 3Y	1.05
Current VS TTM Avg	+35.15%
Current VS 3Y Avg	+84.39%
Current VS 5Y Avg	+129.69%

Ev/Sales Ratio	20355142.90
Ev/Sales Ratio Avg TTM	8390802.46
Ev/Sales Ratio Avg 3Y	107.27
Current VS TTM Avg	+142.59%
Current VS 3Y Avg	+18975550.44%
Current VS 5Y Avg	+24307019.48%

Current Ratio	15.82
Current Ratio Avg TTM	17.90
Current Ratio Avg 3Y	11.63
Current VS TTM Avg	-11.59%
Current VS 3Y Avg	+36.07%
Current VS 5Y Avg	+46.39%

Quick Ratio	15.82
Quick Ratio Avg TTM	17.90
Quick Ratio Avg 3Y	11.63
Current VS TTM Avg	-11.59%
Current VS 3Y Avg	+36.07%
Current VS 5Y Avg	+46.73%

ROIC	(42.92%)
ROIC Avg 3Y	(90.74%)
ROIC Avg 5Y	(56.58%)
Current VS 3Y Avg	+52.70%
Current VS 5Y Avg	+24.14%
Current VS 10Y Avg	+21.78%

ROA	(37.07%)
ROA Avg TTM	(10.92%)
ROA Avg 3Y	(18.53%)
Current VS TTM Avg	-239.45%
Current VS 3Y Avg	-100.10%
Current VS 5Y Avg	-130.72%

ROE	(39.55%)
ROE Avg TTM	(43.02%)
ROE Avg 3Y	(88.05%)
Current VS TTM Avg	+8.06%
Current VS 3Y Avg	+55.08%
Current VS 5Y Avg	+28.12%

Net Profit Margin	0.00%
Net Profit Margin Avg TTM	0.00%
Net Profit Margin Avg 3Y	0.00%
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	+100.00%

Gross Profit Margin	0.00%
Gross Pft Margin Avg TTM	0.00%
Gross Pft Margin Avg 3Y	0.00%
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	-100.00%

Tax Rate	0.00%
Tax Rate Avg 3Y	N/A
Tax Rate Avg 5Y	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A
Current VS 10Y Avg	N/A